股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 業聚醫療集團控股有限公司 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06929 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | III.已發行股份及 ...

EF001 第 2 頁 共 2 頁 v 1.1.1 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 業聚醫療集團控股有限公司 | | 股份代號 | 06929 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年十二月三十一日止年度之末期股息 | | 公告日期 | 2026年3月12日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.12 HKD | | 股東批准日期 | 2026年6月8日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0 ...

Financial Performance - For the fiscal year ending December 31, 2025, the company reported a revenue of $180,454,000, representing a 10.0% increase from $164,097,000 in 2024[4] - The gross profit for the same period was $122,431,000, up 7.0% from $114,467,000 in the previous year[4] - The core operating profit, a non-HKFRS measure, increased by 20.2% to $34,833,000 from $28,991,000[4] - The basic earnings per share rose to 5.09 cents, a 5.8% increase compared to 4.81 cents in 2024[5] - The net profit attributable to the owners of the company was $41,899,000, reflecting a 5.5% increase from $39,717,000 in 2024[5] - The company reported a net profit margin of 23.2%, down 1.0 percentage point from 24.2% in the previous year[4] - The company reported a basic earnings per share of $5.09 for the year ending December 31, 2025, compared to $4.81 for 2024, reflecting an increase of approximately 5.85%[39] - The diluted earnings per share for the same period was $5.08, up from $4.81 in 2024, indicating a similar growth trend[41] - The company recorded a net profit attributable to shareholders of $41.9 million for the year ended December 31, 2025, an increase of 5.5% from $39.7 million in the previous year[87] Dividends and Shareholder Returns - The company declared a final dividend of 12 HK cents per share, which is a 20.0% increase from 10 HK cents in the prior year[4] - The total dividend proposed for the year ending December 31, 2025, is $12.738 million, an increase from $10.610 million in 2024, reflecting a growth of about 19.98%[50] - The company proposed a final cash dividend of HKD 0.12 per share, up from HKD 0.10 per share in 2024, along with a special cash dividend of HKD 0.15 per share to celebrate its 25th anniversary[53] Assets and Liabilities - The total assets as of December 31, 2025, amounted to $452,910,000, compared to $431,010,000 in 2024[10] - The total liabilities rose to $38,711 thousand in 2025, up from $36,633 thousand in 2024, indicating an increase of about 5.7%[11] - Current liabilities totaled $33,265 thousand in 2025, compared to $30,723 thousand in 2024, reflecting a rise of approximately 8.3%[11] - Non-current liabilities decreased to $5,446 thousand in 2025 from $5,910 thousand in 2024, showing a decline of about 7.8%[11] - Total equity attributable to the company's owners increased to $413,053 thousand in 2025 from $393,309 thousand in 2024, representing a growth of approximately 5.3%[11] Revenue Sources and Market Performance - Revenue from external customers in the Asia-Pacific region for 2025 was $60,467,000, compared to $52,241,000 in 2024, marking an increase of about 15.5%[22] - The company’s revenue from the United States in 2025 was $21,204,000, compared to $15,475,000 in 2024, indicating a growth of approximately 37.0%[22] - The company’s total revenue from external customers in China reached $70,782,000 in 2025, a slight decrease from $66,225,000 in 2024, representing a decline of about 6.0%[22] - The Asia-Pacific region saw a significant revenue increase of approximately 15.7%, reaching $60.5 million, driven by sales growth of key products[54] - Revenue in the Europe, Middle East, and Africa region accelerated to $46.9 million, a substantial year-on-year increase of 19.6%[55] - Sales in the Asia-Pacific region increased by $8.2 million, driven by higher sales of COMBO Plus stents and various balloon products in Indonesia, Hong Kong, Singapore, and Malaysia[75] - Sales in Europe, the Middle East, and Africa rose by $7.7 million, mainly due to increased sales of Sapphire 3 and new product SUPPORT C in Germany, Spain, and France[75] Expenses and Costs - The total expenses for 2025 amounted to $141,138,000, an increase from $129,372,000 in 2024, which is an increase of about 9.1%[30] - The immediate income tax expense for 2025 was $6,178,000, an increase from $4,320,000 in 2024, which is an increase of about 43.0%[32] - Sales and distribution expenses increased by 13.5% to $42.5 million, driven by higher employee benefits and marketing expenses[80] - Research and development expenses decreased by 7.7% to $15.7 million for the year ended December 31, 2025, mainly due to reduced clinical trial costs[83] Cash Flow and Financial Position - The company’s cash and bank balances decreased to $218,704,000 from $248,590,000 in the previous year[10] - The group maintained a strong financial position with approximately $228.7 million in cash and bank balances, allowing for potential acquisitions and new facility construction[72] - The total current assets as of December 31, 2025, were approximately $350.7 million, compared to $361.5 million as of December 31, 2024, indicating a decrease of about 3.2%[90] - The net current asset value as of December 31, 2025, was $317.4 million, a decrease of 4.0% from $330.7 million as of December 31, 2024[91] Strategic Initiatives and Future Outlook - The company is actively expanding its business into the structural heart disease sector, indicating a strategic focus on growth in new markets[51] - The company anticipates revenue growth in 2026, driven by new product launches and sales, with a focus on direct sales models in various markets[70] - The company plans to establish new direct sales teams in the Netherlands and Belgium to strengthen its market presence in Europe[72] - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of F million set aside for this purpose[122] - A new strategic partnership has been established, expected to drive G% growth in sales through collaborative efforts in product development[122] Corporate Governance and Compliance - The financial statements are prepared in accordance with Hong Kong Financial Reporting Standards, ensuring compliance with local regulations[15] - The audit committee reviewed the consolidated financial statements for the year ending December 31, 2025, and found them to comply with applicable accounting standards and regulations[109] - The company is committed to reviewing and enhancing its corporate governance practices to comply with the corporate governance code[107] - The company has adopted a policy for securities trading by directors and employees, confirming compliance for the year ending December 31, 2025[108]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06929 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | 本月底法定/註冊股本總額： USD 600,000 第 1 頁 共 10 頁 v 1.2.0 截至月份: 2026年2月28日 狀態: 新 ...

承董事會命 業聚醫療集團控股有限公司 董事長、執行董事兼首席執行官 錢永勛先生 於本公告日期，董事會包括執行董事錢永勛先生、劉桂禎女士及陳泳成先生；非執行董事梁鼎新先 生；以及獨立非執行董事陳業強先生、樓家強先生 BBS、MH、JP 及譚麗芬醫生。 （於開曼群島註冊成立的有限公司） （股份代號：6929） 董事會會議召開日期 業聚醫療集團控股有限公司（「本公司」）董事會（「董事會」）茲通告謹定於二零二六年 三月十二日（星期四）舉行董事會會議，藉以（其中包括）考慮及批准本公司及其附屬 公司截至二零二五年十二月三十一日止之全年業績及其刊發、考慮派發末期股息 （如有）及處理其他任何事務。 香港，2026年3月2日 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 OrbusNeich Medical Group Holdings Limited 業聚醫療集團控股有限公司 ...

Core Insights - The report highlights changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies. Group 1: Recent Increases in Holdings - VITASOY INT'L (00345) saw an increase of 0.09%, bringing its latest holding percentage to 3.75% [1] - 恒生科技ETF (03032) increased by 0.04%, with a current holding of 18.49% [1] - 永升服务 (01995) experienced a rise of 0.01%, now holding 4.57% [1] - 南方东西精选 (03441) had the largest increase over five days at 18.46%, reaching 41.03% [4] - 喜相逢集团 (02473) increased by 10.04%, with a holding of 45.14% [4] - 兆易创新 (03986) rose by 4.95%, now at 6.65% [4] Group 2: Recent Decreases in Holdings - 南方恒生科技 (03033) experienced the largest decrease of -0.14%, with a current holding of 68.87% [2] - 医渡科技 (02158) decreased by -0.03%, now at 22.59% [2] - 盈富基金 (02800) saw a reduction of -0.02%, with a holding of 3.49% [2] - 山东墨龙 (00568) had a five-day decrease of -1.30%, now at 53.56% [5] - 亿华通 (02402) decreased by -1.00%, with a holding of 27.49% [5] - 国富氢能 (02582) saw a reduction of -0.90%, now at 20.14% [5] Group 3: Long-term Trends in Holdings - Over a 20-day period, 喜相逢集团 (02473) had the highest increase of 42.45%, reaching 45.14% [6] - 南方东西精选 (03441) increased by 27.31%, now at 41.03% [6] - 钧达股份 (02865) rose by 15.74%, with a holding of 64.80% [6] - 天齐锂业 (09696) experienced a significant decrease of -6.48%, now at 31.50% [6] - 金风科技 (02208) decreased by -5.88%, with a holding of 42.49% [6]

| 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06929 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | 本月底法定/註冊股本總額： USD 600,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 業聚醫療集團控股有限公司 呈交日期: 2026年2月 ...

Core Insights - The coronary access devices are essential consumables for percutaneous coronary intervention (PCI) surgeries, directly impacting surgical outcomes and complication control [1][6] - The industry is supported by a series of policies in China, including centralized procurement, innovation approvals, and grassroots medical construction, laying a solid foundation for high-quality development [6][10] - The number of coronary artery disease patients is steadily increasing globally and in China, with projections indicating 220 million patients worldwide and 27.879 million in China by 2024, highlighting significant growth potential for the industry [10] Industry Overview - Coronary access devices are specialized medical equipment and consumables used in PCI surgeries to establish and maintain access from the body surface to the coronary arteries, ensuring the smooth execution of angiography, balloon dilation, and stent implantation [1][6] - The devices are categorized into four main types: puncture devices, catheter systems, sheath sets, and auxiliary devices for pressure monitoring and vascular closure [3][4] Development Background - The development of coronary access devices is crucial for reducing cardiovascular disease mortality, enhancing medical accessibility, and promoting high-end device localization [6][8] - Recent policies in China aim to improve centralized procurement mechanisms, accelerate innovation device approvals, and standardize medical insurance payments, providing guidance for industry development [6][10] Market Analysis - The global coronary balloon dilatation catheter market is expanding, with functional balloons growing at a faster rate; the market size is expected to increase from $560 million in 2020 to $960 million in 2024, with a compound annual growth rate (CAGR) of 8.49% [12][14] - In China, the market is characterized by structural adjustments and rapid growth, with the general balloon market experiencing a temporary decline due to centralized procurement but expected to rebound, while functional balloons are projected to grow significantly, with a CAGR of 19.28% from 2024 to 2028 [14][16] Competitive Landscape - The competitive landscape of the coronary access device industry is tiered, with foreign companies dominating the high-end market while domestic leaders are accelerating their market penetration; by 2024, domestic companies are expected to capture 54.9% of the coronary balloon market [14][15] Future Trends - The industry is expected to evolve along three main directions: technological upgrades, deepening domestic substitution, and expansion of grassroots markets [16] - Innovations such as biodegradable materials and smart functions will drive high-end product iterations, while local companies will enhance core component localization through material and manufacturing process advancements [17][18] - The promotion of tiered diagnosis and treatment will reshape market demand, with a growing need for cost-effective and standardized products suitable for grassroots settings [18]

Policy Developments - The Ministry of Commerce and nine other departments issued an opinion to promote the high-quality development of the pharmaceutical retail industry, proposing 18 specific measures focused on improving pharmaceutical services and emergency supply guarantees [1] - The opinion emphasizes the development of smart regulation, including accurate collection and verification of drug traceability codes and uploading to a national medical insurance information platform [1] - A dynamic regulatory model based on risk levels and credit evaluations will be implemented, optimizing inspection frequencies for low-risk enterprises and exploring non-on-site supervision methods like AI video inspections [1] Drug Approval - Yuandong Bio's subsidiary Shod Pharmaceutical received a drug registration certificate for chloral hydrate syrup, aimed at sedation and hypnosis for children, marking the company's first approved Class 2 modified new drug [2] - West Point Pharmaceutical announced the approval of glucosamine sulfate capsules for primary or secondary osteoarthritis, enhancing its product line but facing sales uncertainties due to industry policies and procurement factors [3] Capital Market - OpenEvidence, a medical AI startup, completed a $250 million Series D financing round, achieving a valuation of $12 billion, with total financing nearing $700 million [4] - West Point Pharmaceutical plans to repurchase shares worth between 25 million and 50 million RMB, with a maximum repurchase price of 42.00 RMB per share, representing 0.78% to 1.56% of its total A-share capital [5] Industry Developments - Baichuan Intelligent launched the evidence-enhanced medical model M3 Plus, reducing hallucination rates to 2.6%, the lowest globally, and introduced the "evidence anchoring" technology to link generated medical conclusions to original research [6][7] - Sinovac's inactivated hepatitis A vaccine has secured a two-year exclusive bid in Oman, with over 130 million doses supplied globally, making it one of the most widely used hepatitis A vaccines [8] Public Opinion Alerts - Yiju Medical announced the resignation of non-executive director Dr. Zhou Yi, effective January 22, 2026, to focus on other business commitments [9]

Group 1 - The company, Yiju Medical (06929), announced that Dr. Zhou Yi has resigned from his position as a non-executive director to dedicate more time to other business commitments, effective from January 22, 2026 [1]